Status:
UNKNOWN
Epsilon Aminocaproic Acid Vs. Tranexamic Acid Vs. Placebo for Prevention of Blood Loss in Total Knee Arthroplasty
Lead Sponsor:
Heekin Orthopedic Research Institute
Conditions:
Osteoarthritis
Eligibility:
All Genders
21+ years
Phase:
NA
Brief Summary
TXA and EACA have been reported to reduce blood loss in cardiac and neuro surgery, but there is no literature available comparing the two in total knee arthroplasty (TKA). The investigators want to de...
Eligibility Criteria
Inclusion
- All patients scheduled to receive primary unilateral total knee arthroplasty
Exclusion
- Subject requires bilateral staged total knee arthroplasty
- Religious beliefs that would limit blood transfusion
- History of acquired defective color vision (inhibits monitoring for adverse events)
- Patients with a known history of upper urinary tract bleeding
- History of abnormal coagulation
- Renal dysfunction defined by elevated BUN and CR or BUN to CR ratio of 20:1 within 30 days of surgery
- Active intravascular clotting
- Known allergy to either TXA or eACA
- Myocardial Infarct within 6 months
- History of stroke
- Patient is a prisoner
Key Trial Info
Start Date :
April 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01527968
Start Date
April 1 2012
End Date
December 1 2016
Last Update
July 26 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.